ArticleClinical, cosmetic and investigational dermatology2016
Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth.
Article in Clinical, cosmetic and investigational dermatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials.Anais brasileiros de dermatologiaPooled it
- Recent Advances in the Role of Fibroblast Growth Factors in Hair Follicle Growth.Biomolecules · 2025Review
- Article
- Platelet-rich plasma: a comparative and economical therapy for wound healing and tissue regeneration.Cell and tissue banking · 2023Review
- Cost-effectively dissecting the genetic architecture of complex wool traits in rabbits by low-coverage sequencing.Genetics, selection, evolution : GSE · 2022Article
- Article
- Review
- [Clinical effects of follicle unit extraction transplantation combined with recombinant bovine basic fibroblast growth factor and minoxidil in the treatment of secondary cicatricial alopecia].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021Observational
- Development of Novel Heparin/Protamine Nanoparticles Useful for Delivery of Exogenous Proteins In Vitro and In Vivo.Nanomaterials (Basel, Switzerland) · 2020Article
- 3,4,5-Tri-Frontiers in cell and developmental biology · 2020Article
- Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers.Molecules (Basel, Switzerland) · 2019Review
- Article
- Skin transcriptome reveals the dynamic changes in the Wnt pathway during integument morphogenesis of chick embryos.PloS one · 2018Article
- A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification.Skin appendage disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough treatments for alopecia are in high demand, not all treatments are safe and reliable. Dalteparin/protamine nanoparticles (D/P NPs) can effectively carry growth factors (GFs) such as fibroblast GF (FGF)-2. The purpose of this study was to identify the effects of FGF-2-containing D/P NPs (FGF-2&D/P NPs) on hair growth. PATIENTS AND
methodsIn this study, the participants were 12 volunteers with thin hair. One milliliter of FGF-2 (100 ng/mL) and D/P NPs (56 μg/mL) was applied and massaged on the skin of the scalp by the participants twice a day. They were evaluated for 6 months. Participants were photographed using a digital camera for general observation and a hair diagnosis system for measuring hair diameter.
resultsThe mean diameter of the hairs was significantly higher following the application of FGF-2&D/P NPs for 6 months. Objective improvements in thin hair were observed in two cases. Nine participants experienced greater bounce and hair resilience.
conclusionThe transdermal application of FGF-2&D/P NPs to the scalp can be used as a new treatment for alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.